Integra CEO Jan De Witte to retire, Stuart Essig named executive chairman
IART
+0.27%
Add to/Remove from Watchlist
Add to Watchlist
Add Position
Position added successfully to:
Please name your holdings portfolio
Type:
BUY
SELL
Date:
Amount:
Price
Point Value:
Leverage:
1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000
Commission:
Create New Watchlist
Create
Create a new holdings portfolio
Add
Create
+ Add another position
Close
PRINCETON, N.J. — Integra LifeSciences Holdings Corporation (NASDAQ: IART), a prominent medical technology firm, has announced that its CEO Jan De Witte plans to retire by the end of 2024. Concurrently, the company’s chairman Stuart Essig has been appointed as the executive chairman effective immediately.
De Witte, who has been at the helm of Integra, expressed pride in the company’s achievements and his gratitude to the board and Integra’s team. He emphasized the company’s focus on operational execution, particularly in manufacturing and supply chain, to achieve its 2024 objectives.
Essig, who has served as Integra’s non-executive chairman since 2012 and was CEO from 1997 to 2012, will now oversee the transition and strive to enhance shareholder value. The board has initiated a search for a new CEO with Heidrick & Struggles (NASDAQ:HSII), aiming to find a candidate with a strong track record in the industry.
The leadership change was discussed during Integra’s financial results conference call for the fourth quarter and full-year 2023, which took place today at 8:30 a.m. ET.
Integra LifeSciences is known for its diverse portfolio of medical products and is committed to advancing patient outcomes in surgery, neurology, and regenerative care. The company’s strategy includes a focus on commercial acceleration through product development, digital innovation, strategic acquisitions, and growth in international markets.
The news of De Witte’s retirement and Essig’s new role is based on a press release statement. Integra continues to navigate the competitive landscape of the medical technology industry, maintaining its dedication to innovation and patient care.
